24 results about "Viral entry" patented technology

This invention relates to an anti-swine pseudorabies virus (PRV) preparation and the application of Rehmannia glutinosa polysaccharide in its preparation, belonging to the field of biopharmaceutical technology. This invention provides an anti-swine pseudorabies virus (PRV) preparation comprising Rehmannia glutinosa polysaccharide. It also provides the application of Rehmannia glutinosa polysaccharide in the preparation of an anti-PRV preparation for the prevention and / or treatment of swine pseudorabies. This invention utilizes Rehmannia glutinosa polysaccharide to prevent infection by the PRV variant XJ5 by reducing intracellular oxidative stress levels; it also resists viral infection by affecting viral adsorption. Furthermore, when the concentration of Rehmannia glutinosa polysaccharide is between 50 and 400 μg / mL, it can also affect viral entry and replication, and has no cytotoxicity to PK-15 cells.

The present invention provides a mammalian cell line that has been genetically engineered to make it resistant to viral entry and / or replication; and provides a method for using the cell line to reduce or prevent viral contamination of a bioproduction system.

The application relates to the field of biological medicine, and particularly relates to application of Navitoclax (ABT263) in preparation of a broad-spectrum antiviral inhibitor. The application of the compound Navitoclax (ABT263), an analogue or a salt thereof shown in formula (I) in preparation of a broad-spectrum antiviral inhibitor. It is found in the application that the compound has broad-spectrum antiviral activity, including but not limited to SARS-CoV-2, SARS-CoV, MERS-CoV, the compound can act on the virus entry stage, and the virus is resisted outside the target cell. In addition, the compound has a high selection index (CC50 / IC50) for different viruses, and has considerable safety. The application provides a broad-spectrum antiviral small-molecule compound, which has the advantages of simple preparation method, low cost, easy transportation and storage, high safety and good activity, and has a broad prospect in the fields of biological medicine and response to new emerging infectious diseases.

This disclosure relates to methods of treating a coronavirus infection or other microbial infection comprising administering an effective amount of a plant extract, or compound, or combination of compounds derived therefrom to a subject in need thereof. In certain embodiments, the plant extract is obtained by a process of contacting a segment of a plant a with a solvent providing an extract as reported herein. In certain embodiments, this disclosure contemplates pharmaceutical compositions comprising extracts and components contained therein for use in methods of treating viral or other microbial infections.

The present invention relates to the treatment of inflammatory diseases. Here, the inventors analyzed the immune activation triggered by HRV16 in macrophages to elucidate the cellular pathways involved in ARL5b upregulation. They demonstrated that HRV16 does not replicate in macrophages but induces interferon and pro-inflammatory responses. Conversely, in HeLa OHIO cells where the virus replicates, no induction of immune responses is observed. They identify the ICAM1-PKR-ATF2 axis as the primary regulator of HRV16-mediated ARL5b induction in macrophages. By contrast, HRV16-mediated ARL5b decrease in HeLa OHIO is dependent on ICAM-1 / viral entry in the cells but not on PKR signalling. Finally, ARL5b is regulated at the epigenetic level in both HeLa OHIO and human macrophages. An increase in the repressive mark H3K27Me3 is observed in HeLa OHIO, while the activating mark H3K27Ac is increased on the ARL5b promoter in human macrophages. Thus, the invention relates to relates to an inhibitor of the ICAM1 / PKR / ATF2 signalling pathway for use in the improvement of phagocytosis in a subject in need thereof.

To provide a mask capable of: 100% completely preventing droplet infection of novel coronavirus in particular, including to the eyes; allowing wearers to have clear conversation, preventing a transparent plate and glasses from fogging; being usable by women without ruining makeup, being usable over a long period of time; etc.SOLUTION: A mask dedicated to novel coronavirus, is designed to enhance rigidity by bending a flat transparent plate to improve temperature and humidity, prevents virus entry by increasing internal temperature and atmospheric pressure humidity, completely blocks virus droplets from reaching the eyes, nose, and mouth without touching the eyes, nose, and mouth, expels exhaled air to prevent the transparent plate and glasses from fogging, allows wearers to have clear conversation, keeps women's makeup from coming off, can be put in a pocket, allows eating, doubles as an eye mask, is a world's first so-called face shield, and has a highest performance and widest range of uses.SELECTED DRAWING: Figure 4

The invention relates to anti-viral compounds suitable for use in blocking virus entry into cells, and methods of blocking virus entry into cells by associating the cells with the anti-viral compounds. The associating may occur in vitro, or in vivo in a subject through administration of the anti-viral compounds to the subject. The invention also relates to methods of treating or preventing a viral infection in a subject by administering to the subject at least one anti-viral compound. The subject may be a human being suffering from or vulnerable to the viral infection. The virus may include a coronavirus, such as severe acute respiratory syndrome-related coronavirus 2 (SARS-COV-2).

This invention discloses a fermented traditional Chinese medicine preparation for treating porcine epidemic diarrhea virus infection and its application. This fermented traditional Chinese medicine preparation is obtained by fermenting dandelion, isatis root, alisma, kudzu root, scutellaria, licorice, and hawthorn using a probiotic mother liquor. The probiotic mother liquor contains *Lactobacillus rhamnoides*, *Bacillus subtilis*, *Lactobacillus plantarum*, and *Bacillus coagulans*. The preparation method of this fermented traditional Chinese medicine preparation includes the following steps: (1) mixing the herbs, decocting, filtering, and sterilizing to obtain a mixed herbal liquid; (2) adding the probiotic mother liquor to the mixed herbal liquid for fermentation to obtain the fermented traditional Chinese medicine liquid. This fermented traditional Chinese medicine preparation can exert its anti-porcine epidemic diarrhea virus effect in vitro by preventing the virus from entering cells, inhibiting viral replication, and directly killing the virus. It has a significant preventive and therapeutic effect on diseases caused by this virus, is easy to prepare, can be mass-produced, and is beneficial to improving the economic benefits of pig farms.

The invention relates to the technical field of gene engineering, in particular to an avian infectious bronchitis virus system based on double reporter genes and application thereof. According to the avian infectious bronchitis virus system based on the double reporter genes, real-time monitoring of IBV infection and replication can be achieved, the detection sensitivity and specificity are improved, meanwhile, experimental operation is simplified, and cost is reduced. The system can be used for various applications including but not limited to virus susceptible cell testing, virus entry mechanism research, antiviral drug screening, vaccine and neutralizing antibody effect evaluation, virus intrusion inhibitor evaluation and influence research of virus variation on infectivity. The system and the method provided by the invention provide a new tool for research and prevention and control of IBV and other enveloped viruses, and have important scientific and practical application values.

This invention discloses a method for manufacturing a negative ion device for preventing and treating airborne viral infections. Specifically, water is added to tourmaline pebbles to moisten them, but not completely immerse them, and additional air pressure is applied to the surface of the wet tourmaline pebbles. The pressure of the tourmaline is used to generate a pressure-electric electrode that is far greater than the spontaneous polarization effect, ionizing surrounding water molecules to produce a large number of hydroxide and hydrogen ions. Hydrogen ions have a weaker electron-capturing ability compared to oxygen molecules and are the lightest substance, so they disperse immediately after being blown out by the fan, resulting in a very low content in the environment. After the hydroxide ions donate electrons, water and oxygen are produced, and the electrons that donate them combine with oxygen molecules blown in by the fan and oxygen molecules produced by their own reactions to form intrinsic negative ions by Brownian motion. Using these negative ions obtained through the Green method, it is possible to promote the decomposition of VOCs, condense and settle PM2.5, aerosols, bacteria, viruses, pollen, etc., inhibit or kill bacteria, change or reverse the polarity of the potential inside and outside the viral capsid, break down the viral spike, rapidly inactivate viruses, and prevent viruses from entering human cells by blocking electrostatic attraction between the viral receptor binding region and the cell membrane receptor. At the same time, it has other health and therapeutic effects such as alleviating respiratory allergies, improving respiratory and circulatory functions, aiding sleep, preventing fatigue, antioxidant, removing free radicals in the body, increasing the body's repair capacity, and enhancing immunity. It can also generate and replenish diffused oxygen and perform mist-free humidification.

The invention relates to an application of torreya grandis aril volatile oil in preparation of a medicine for resisting porcine epidemic diarrhea virus. The torreya grandis aril volatile oil is volatile oil extracted from torreya grandis' Merrillii 'Hu aril of a torreya plant of taxus chinensis family. Researches show that the torreya grandis aril volatile oil can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the porcine epidemic diarrhea viruses, and can be applied to preparation of the medicines for resisting the porcine epidemic diarrhea viruses. The torreya grandis aril volatile oil is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.

Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include a trimerizing domain (e.g., a collagen 18 trimerizing domain) attached through a peptide linker to a viral protein binding domain (e.g., a spike binding domain). The peptides and trimeric compositions provided herein exhibit a unique trimeric symmetry which results in superior binding affinities and low binding entropies providing for desirable compositions inhibit viral entry and treating viral infection.

The present invention relates to the treatment of inflammatory diseases. Here, the inventors analyzed the immune activation triggered by HRV16 in macrophages to elucidate the cellular pathways involved in ARL5b upregulation. They demonstrated that HRV16 does not replicate in macrophages but induces interferon and pro-inflammatory responses. Conversely, in HeLa OHIO cells where the virus replicates, no induction of immune responses is observed. They identify the ICAM1-PKR-ATF2 axis as the primary regulator of HRV16-mediated ARL5b induction in macrophages. By contrast, HRV16-mediated ARL5b decrease in HeLa OHIO is dependent on ICAM-1 / viral entry in the cells but not on PKR signalling. Finally, ARL5b is regulated at the epigenetic level in both HeLa OHIO and human macrophages. An increase in the repressive mark H3K27Me3 is observed in HeLa OHIO, while the activating mark H3K27Ac is increased on the ARL5b promoter in human macrophages. Thus, the invention relates to relates to an inhibitor of the ICAM1 / PKR / ATF2 signalling pathway for use in the improvement of phagocytosis in a subject in need thereof.

The invention discloses application of a radix tetrastigme extract in preparation of a medicine for resisting Crimean-Congo hemorrhagic fever virus, and belongs to the technical field of medicine. The anti-CCHFV effect of the radix tetrastigme extract is evaluated on the cellular level by utilizing a CCHFV virus-like particle system capable of simulating virus endocytosis and transcriptional activity, and the result shows that the radix tetrastigme extract has remarkable antiviral activity, is dose-dependent, and has a good application prospect. The antiviral activity mechanism of the radix tetrastigme extract is related to virus cell entry and virus transcription stages. The radix tetrastigme extract provided by the invention shows the activity of inhibiting the CCHFV, and has a wide prospect of being developed into a medicine for treating human CCHFV infection.

The invention relates to an application of polygonum capitatum or an extract of the polygonum capitatum in preparation of an anti-pseudorabies virus drug. The polygonum capitatum is a dry whole herb or an overground part of polygonum capitatum Poly (Polygonum capitatum Buck.-Ham. Ex D.Don) which is a polygonaceae plant. Researches show that the polygonum capitatum extract can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the pseudorabies viruses, the effect of inhibiting the proliferation of the pseudorabies viruses is remarkably superior to that of an antiviral chemical drug acyclovir, and the polygonum capitatum extract can be applied to preparation of the pseudorabies virus resisting medicine. The polygonum capitatum extract is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.

This invention discloses a chimeric antiviral cross-protective antigen mRNA vaccine, its preparation method, and its application. The vaccine consists of lipid materials encapsulating either a first or second type of mRNA, forming nanolipid nanoparticles containing mRNA fragments. The first type of mRNA is obtained through in vitro transcription using a first DNA template, and the second type of mRNA is obtained through in vitro transcription using a second DNA template. The vaccine of this invention possesses the advantage of multi-antigen comprehensive immunity: each vaccine combines one EEV core surface antigen and one IMV core surface antigen. This chimeric strategy can simultaneously induce highly efficient and specific immunity against both types of viral infection particles, both limiting initial viral entry into cells and effectively clearing free viruses from the circulatory system. It not only stimulates strong humoral immunity but also induces specific cellular immune responses, thereby significantly enhancing the vaccine's broad-spectrum cross-protective efficacy against orthopox, vaccinia virus, and other orthopox viruses.

To provide a mask capable of: 100% completely preventing droplet infection of novel coronavirus in particular, including to the eyes; allowing wearers to have clear conversation, preventing a transparent plate and glasses from fogging; being usable by women without ruining makeup, being usable over a long period of time; etc.SOLUTION: A mask dedicated to novel coronavirus, is designed to enhance rigidity by bending a flat transparent plate to improve temperature and humidity, prevents virus entry by increasing internal temperature and atmospheric pressure humidity, completely blocks virus droplets from reaching the eyes, nose, and mouth without touching the eyes, nose, and mouth, expels exhaled air to prevent the transparent plate and glasses from fogging, allows wearers to have clear conversation, keeps women's makeup from coming off, can be put in a pocket, allows eating, doubles as an eye mask, is a world's first so-called face shield, and has a highest performance and widest range of uses.SELECTED DRAWING: Figure 4

The present application relates to viral entry inhibitors and RNA polymerase inhibitors, pharmaceutical compositions comprising one or more of the same, and combination therapies, as well as methods of making and of using the foregoing in the treatment of certain diseases.

The invention relates to an application of polygonum capitatum or an extract of the polygonum capitatum in preparation of a medicine for resisting porcine epidemic diarrhea virus. The polygonum capitatum is a dry whole herb or an overground part of polygonum capitatum Poly (Polygonum capitatum Buck.-Ham. Ex D.Don) which is a polygonaceae plant. Researches show that the polygonum capitatum extract can effectively and directly kill viruses, prevent the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the porcine epidemic diarrhea viruses, and can be applied to preparation of the medicine for resisting the porcine epidemic diarrhea viruses. The polygonum capitatum extract is rich and cheap in raw materials, simple in preparation process and low in cost, and has good development and application prospects.

A pharmaceutical composition with dual anti-inflammatory and antiviral activity against COVID-19 and related respiratory pathogens, the composition comprising the following: (a) Curcumin in an amount of 1.5 to 5.0% by weight, which acts as a primary anti-inflammatory agent, suppressing cyclooxygenase-2 (COX-2) expression and interleukin-6 (IL-6) signaling; b) Quercetin in an amount of 2.0 to 6.0 wt%, which acts as an antiviral flavonoid and is able to inhibit SARS-CoV-2 proteases (3CLpro and PLpro) and the penetration of the virus; (c) Zinc oxide nanoparticles (ZnO-NPs) in an amount of 0.5 to 2.0 wt%, with an average particle size between 20 and 40 nm, which facilitate the destruction of viral envelope proteins and increase cellular zinc uptake; d) Ascorbic acid (vitamin C) in an amount of 1.0 to 4.0 wt.%, which acts as an antioxidant to neutralize reactive oxygen species (ROS) produced during viral infections and inflammatory reactions; (e) Glycyrrhizin, extracted from licorice glabra, in an amount of 1.0 to 3.0% by weight, acts as an immunomodulator, stabilizes cytokine levels and reduces pneumonia; and (f) a pharmaceutically acceptable carrier medium consisting of liposomal, polymeric or PEG-based excipients in an amount of 80 to 90 wt.%, which ensures sustained release and improved bioavailability of the active substances.

The disclosure concerns preventing or treating a viral infection in an individual, comprising administering a HAT inhibitor to the individual. The disclosure further concerns a HAT inhibitor for use in the method of the disclosure, and use of a HAT inhibitor in the manufacture of a medicament for preventing or treating a viral infection in an individual. In addition, the disclosure concerns a related method of screening for a treatment for a viral infection.

The invention relates to an application of illicium henryi or an extract of the illicium henryi in preparation of a medicine for resisting porcine epidemic diarrhea viruses. The illicium henryi is a Magnoliaceae plant, namely, Illicium lanceolatum A.C.Smith. The invention further relates to a preparation method of the illicium henryi and the extract of the illicium henryi. Researches show that the illicium henryi extract can effectively and directly kill viruses, block the viruses from entering cells, inhibit the viruses from being copied in the cells and play a role in resisting the porcine epidemic diarrhea viruses, and can be applied to preparation of the medicine for resisting the porcine epidemic diarrhea viruses.

The present invention relates to the identification of cell models that support bocavirus infection and its application. The present invention selected 29 human cell lines derived from kidney, lung, brain, lymphocytes, intestine, muscle, thyroid and mammary gland, and 7 animal cell lines derived from mice, monkeys, dogs, pigs and cattle for evaluation, and found that compared with Caco-2 cells, only HT-29 and MA104 cells had higher levels of intracellular viral RNA transcription; further detection of intracellular viral DNA levels through infection system found that compared with Caco-2 cells, only MA104 supported higher levels of viral replication. Finally, through experimental tests such as virus binding and internalization, virus replication level, virus particle morphology and virus particle reinfection, it was confirmed that human bocavirus type I has a complete life cycle in MA104 cells, including virus entry, replication, assembly and release.